Jason Pomerantz, M.D.

Plastic and reconstructive surgeon

Dr. Jason H. Pomerantz is a plastic surgeon who specializes in pediatric plastic and reconstructive surgery including the treatment of craniofacial anomalies. He cares for children and adults with congenital or acquired deformities, especially of the head and face, such as cleft lip and palate, craniosynostosis and traumatic facial injuries.

Pomerantz earned a medical degree at the Albert Einstein College of Medicine in Mew York and completed a residency at UCSF, a postdoctoral research fellowship in regeneration biology at Stanford University and a fellowship in craniofacial surgery at the University of Washington. His research focuses on tissue regeneration and maintenance by stem cells to optimize tissue repair and correct deformities associated with development, trauma or disease. He is an assistant professor of surgery in the UCSF School of Medicine.

Clinics

Center for Craniofacial Anomalies
513 Parnassus Avenue, S-747
San Francisco, CA 94143-0570
Phone: (415) 476-2271

Plastic and Reconstructive Surgery
400 Parnassus Ave., Sixth Floor, Suite A655
San Francisco, CA 94143-0932
Phone: (415) 353-4201

Conditions & Treatments

More about Jason Pomerantz

Additional Languages

Spanish

Education

Albert Einstein School of Medicine 2000

Residencies

UCSF Medical Center, Plastic Surgery 2008

Fellowships

Stanford University, School of Medicine, Regeneration Biology 2006
University of Washington Medical Center, Craniofacial Surgery 2009

Selected Research and Publications

  1. Tamaki S, Nye C, Slorach E, Scharp D, Blau HM, Whiteley PE, Pomerantz JH. Simultaneous silencing of multiple RB and p53 pathway members induces cell cycle reentry in intact human pancreatic islets. BMC Biotechnol. 2014; 14(1):86.
  2. Pomerantz JH, Blau HM. Tumor suppressors: enhancers or suppressors of regeneration? Development. 2013 Jun; 140(12):2502-12.
  3. Garland CB, Pomerantz JH. Regenerative strategies for craniofacial disorders. Front Physiol. 2012; 3:453.
  4. Blau HM, Pomerantz JH. Re"evolutionary" regenerative medicine. JAMA. 2011 Jan 5; 305(1):87-8.
  5. Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, Shkreli M, Delp S, Pomerantz JH, Artandi SE, Blau HM. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell. 2010 Dec 23; 143(7):1059-71.
  6. Pajcini KV, Corbel SY, Sage J, Pomerantz JH, Blau HM. Transient inactivation of Rb and ARF yields regenerative cells from postmitotic mammalian muscle. Cell Stem Cell. 2010 Aug 6; 7(2):198-213.
  7. Pomerantz JH, Mukherjee S, Palermo AT, Blau HM. Reprogramming to a muscle fate by fusion recapitulates differentiation. J Cell Sci. 2009 Apr 1; 122(Pt 7):1045-53.
  8. Palermo A, Doyonnas R, Bhutani N, Pomerantz J, Alkan O, Blau HM. Nuclear reprogramming in heterokaryons is rapid, extensive, and bidirectional. FASEB J. 2009 May; 23(5):1431-40.
  9. Pajcini KV, Pomerantz JH, Alkan O, Doyonnas R, Blau HM. Myoblasts and macrophages share molecular components that contribute to cell-cell fusion. J Cell Biol. 2008 Mar 10; 180(5):1005-19.
  10. Gruber RP, Weintraub J, Pomerantz J. Suture techniques for the nasal tip. Aesthet Surg J. 2008 Jan-Feb; 28(1):92-100.
  11. Wan DC, Pomerantz JH, Brunet LJ, Kim JB, Chou YF, Wu BM, Harland R, Blau HM, Longaker MT. Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem. 2007 Sep 7; 282(36):26450-9.
  12. Zhang F, Pomerantz JH, Sen G, Palermo AT, Blau HM. Active tissue-specific DNA demethylation conferred by somatic cell nuclei in stable heterokaryons. Proc Natl Acad Sci U S A. 2007 Mar 13; 104(11):4395-400.
  13. Wehrman TS, Raab WJ, Casipit CL, Doyonnas R, Pomerantz JH, Blau HM. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci U S A. 2006 Dec 12; 103(50):19063-8.
  14. Palermo AT, Labarge MA, Doyonnas R, Pomerantz J, Blau HM. Bone marrow contribution to skeletal muscle: a physiological response to stress. Dev Biol. 2005 Mar 15; 279(2):336-44.
  15. Pomerantz J, Blau HM. Nuclear reprogramming: a key to stem cell function in regenerative medicine. Nat Cell Biol. 2004 Sep; 6(9):810-6.
  16. Orlow I, Rabbani F, Chin L, Pomerantz J, Ligeois N, Dudas M, Depinho R, Cordón-Cardó C. Involvement of the Ink4a gene (p16 and p19arf) in murine tumorigenesis. Int J Oncol. 1999 Jul; 15(1):17-24.
  17. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene--two products--two pathways. Trends Biochem Sci. 1998 Aug; 23(8):291-6.
  18. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998 Mar 20; 92(6):713-23.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.